Marije Slingerland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marije Slingerland has a total of 431 co-authors. Here are the top co-authors by number of shared publications:
- Hanneke Wilma Marlies van Laarhoven
Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands
8 shared publications - Laurens Victor Beerepoot
Elisabeth-TweeSteden Hospital
5 shared publications - Lukas J. A. C. Hawinkels
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, Netherlands
5 shared publications - Ellen Kapiteijn
Leiden University Medical Center, Leiden, The Netherlands
4 shared publications - Johanneke E. A. Portielje
Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
4 shared publications - Nienke Aafke De Glas
Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands
4 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Second-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study
Background: Reintroduction of oxaliplatin after first-line treatment might preserve treatment lines and could improve overall survival. Objectives: We investigate whether oxaliplatin reintroduction (OXR) or paclitaxel-ramucirumab (PR) is preferred in terms of overall survival for patients with gastroesophageal adenocarcinoma who have disease progression on first-line treatment. Design: We performed a target trial emulation with a propensity-scored inverse probability weighting approach to resemble a randomized controlled trial. Methods: Observational data was retrieved from the Netherlands Cancer Registry between 2015 and 2018, with a maximum follow-up until 2022. Patients were included if they received a fluoropyrimidine with oxaliplatin in first-line and as subsequent treatment OXR or PR. There was at least 6 months between planned discontinuation of oxaliplatin and disease progression. Results: We included 129 patients in our model and the weighted cohort was well balanced between the two groups. No statistically significant difference in overall survival was observed between treatment groups (HR: 0.76, 95% CI: 0.3–1.5; p = 0.36). Median overall survival was 9.2 months (95% CI: 3.7–25.1) for OXR and 7.9 months (95% CI: 2.8–11.5) for PR ( p = 0.38). Exploratory subgroup analysis did not reach statistical significance. Patients in the OXR-group more often received one or more additional treatment lines, including second-line PR, than patients in the PR group, 47.7% versus 23.3%, respectively. Conclusion: OXR following prolonged response to first-line treatment was associated with similar overall survival compared with PR. In the absence of a demonstrated survival benefit for either treatment, these results propose oxaliplatin reintroduction as a potential option in selected patients.
- 3 June 2026
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 18
Open AccessSecond-line oxaliplatin reintroduction or paclitaxel-ramucirumab in metastatic gastroesophageal cancer: a population-based study
Background: Reintroduction of oxaliplatin after first-line treatment might preserve treatment lines and could improve overall survival. Objectives: We investigate whether oxaliplatin reintroduction (OXR) or paclitaxel-ramucirumab (PR) is preferred in terms of overall survival for patients with gastroesophageal adenocarcinoma who have disease progression on first-line treatment. Design: We performed a target trial emulation with a propensity-scored inverse probability weighting approach to resemble a randomized controlled trial. Methods: Observational data was retrieved from the Netherlands Cancer Registry between 2015 and 2018, with a maximum follow-up until 2022. Patients were included if they received a fluoropyrimidine with oxaliplatin in first-line and as subsequent treatment OXR or PR. There was at least 6 months between planned discontinuation of oxaliplatin and disease progression. Results: We included 129 patients in our model and the weighted cohort was well balanced between the two groups. No statistically significant difference in overall survival was observed between treatment groups (HR: 0.76, 95% CI: 0.3–1.5; p = 0.36). Median overall survival was 9.2 months (95% CI: 3.7–25.1) for OXR and 7.9 months (95% CI: 2.8–11.5) for PR ( p = 0.38). Exploratory subgroup analysis did not reach statistical significance. Patients in the OXR-group more often received one or more additional treatment lines, including second-line PR, than patients in the PR group, 47.7% versus 23.3%, respectively. Conclusion: OXR following prolonged response to first-line treatment was associated with similar overall survival compared with PR. In the absence of a demonstrated survival benefit for either treatment, these results propose oxaliplatin reintroduction as a potential option in selected patients.
- Open Access
- 1 March 2026
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 19, 1-15
Close-to-Patient Models for Gastric Cancer: From Patient-Derived Xenograft Towards a Novel Gastric Cancer Mini-Tumor Model
Purpose: Gastric cancer (GC) is the fifth most lethal form of cancer. Because of its late diagnosis, high intratumor heterogeneity, and the presence of a dense stromal compartment, GC is less susceptible to systemic treatments compared to other tumor types. Many systemic therapies, developed to support curative and palliative treatment for GC and other cancers, did not reach the clinic, which might be due to the fact that preclinical data, obtained from simple cell-based models, does not translate to the complex GC tumor structure and the occurrence of drug resistance. Therefore, this study is aimed to establish fibroblast-rich, close-to-patient models for GC and evaluate their robustness by comparison with the primary GC tissue from the respective patients. Material and Methods: Five different GC models were established: I) a subcutaneous and II) orthotopic patient-derived xenograft (PDX) model, III) an in vitro patient-derived organoid (PDO) model, which was IV) subcutaneously engrafted in vivo, and V) co-cultured with GC fibroblasts to form a novel multicellular fibroblast-rich GC model. Histology, immunohistochemistry, mutational status and tumor/stroma composition were compared between the parental tissues and the various models. Results: Both PDX models reflected the histological structure of the parental tissue, consisting of distinct parenchymal and stromal compartments. Primary tumor mutations were maintained in the PDX, as well as markers of clinical interest, like HER2. Orthotopic GC-PDX models showed high growth rates, accompanied by significant stromal accumulation. GC-PDOs showed histological similarities with parental tissues, maintaining the various histological phenotypes. Engrafted subcutaneously in mice, these organoids generated stroma-rich tumors. To mimic these features in vitro, we established a multicellular model composed of GC-associated fibroblasts and GC organoids, aggregating into complex multicellular structures with high similarity to parental GC tumor tissues. Conclusion: We generated five close-to-patient GC models, which can potentially facilitate preclinical evaluations of novel therapies.
- 1 March 2026
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 19, 1-15
Open AccessClose-to-Patient Models for Gastric Cancer: From Patient-Derived Xenograft Towards a Novel Gastric Cancer Mini-Tumor Model
Purpose: Gastric cancer (GC) is the fifth most lethal form of cancer. Because of its late diagnosis, high intratumor heterogeneity, and the presence of a dense stromal compartment, GC is less susceptible to systemic treatments compared to other tumor types. Many systemic therapies, developed to support curative and palliative treatment for GC and other cancers, did not reach the clinic, which might be due to the fact that preclinical data, obtained from simple cell-based models, does not translate to the complex GC tumor structure and the occurrence of drug resistance. Therefore, this study is aimed to establish fibroblast-rich, close-to-patient models for GC and evaluate their robustness by comparison with the primary GC tissue from the respective patients. Material and Methods: Five different GC models were established: I) a subcutaneous and II) orthotopic patient-derived xenograft (PDX) model, III) an in vitro patient-derived organoid (PDO) model, which was IV) subcutaneously engrafted in vivo, and V) co-cultured with GC fibroblasts to form a novel multicellular fibroblast-rich GC model. Histology, immunohistochemistry, mutational status and tumor/stroma composition were compared between the parental tissues and the various models. Results: Both PDX models reflected the histological structure of the parental tissue, consisting of distinct parenchymal and stromal compartments. Primary tumor mutations were maintained in the PDX, as well as markers of clinical interest, like HER2. Orthotopic GC-PDX models showed high growth rates, accompanied by significant stromal accumulation. GC-PDOs showed histological similarities with parental tissues, maintaining the various histological phenotypes. Engrafted subcutaneously in mice, these organoids generated stroma-rich tumors. To mimic these features in vitro, we established a multicellular model composed of GC-associated fibroblasts and GC organoids, aggregating into complex multicellular structures with high similarity to parental GC tumor tissues. Conclusion: We generated five close-to-patient GC models, which can potentially facilitate preclinical evaluations of novel therapies.
- Open Access
- 27 January 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (2)
Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study
Background: Patients with incurable gastroesophageal adenocarcinoma have an impaired health-related quality of life (HRQOL). Exercise combined with nutritional support may improve this outcome. Careful evaluation of this supportive care strategy is needed to avoid burdening patients at this vulnerable stage with interventions that may offer no (meaningful) benefit. Therefore, this study aims to investigate the effects of a combined exercise and nutritional intervention on HRQOL in patients with incurable gastroesophageal adenocarcinoma. Methods: RADICES (the effect of exeRcise And Diet on quality of life in patients with Incurable Cancer of Esophagus and Stomach) is a multicenter randomized controlled trial aiming to include 196 patients with incurable gastroesophageal adenocarcinoma. Participants are randomly assigned (1:1) to a patient-tailored intervention or a control group. The intervention group is provided with 2 training sessions per week and biweekly nutritional consultations, delivered by trained physiotherapists and dietitians, during 12 weeks. The control group receives usual care supplemented with general physical activity advice. The primary outcome is the difference in HRQOL between the intervention group and the control group at 12 weeks, accounting for baseline HRQOL, measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–30 summary score. HRQOL is assessed at baseline, 6 weeks, 12 weeks, and every 3 months thereafter up to 1 year. Key secondary outcomes include patient-reported outcomes, cardiorespiratory fitness, dietary intake, disease progression, overall survival, and cost-effectiveness. Adherence and safety are monitored throughout the intervention period. Conclusion: This study will generate evidence on the effectiveness of a patient-tailored combined exercise and nutritional intervention in patients with incurable gastroesophageal adenocarcinoma. If effective for HRQOL, this intervention could be integrated into standard care for patients with incurable gastroesophageal adenocarcinoma. Trial registration: clinicaltrials.gov NCT06138223. Date of trial registration: November 18, 2023 Date and version study protocol: 28-04-2025 version 3.1 Date start recruitment: 19-01-2024
- 27 January 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (2)
Open AccessEffects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study
Background: Patients with incurable gastroesophageal adenocarcinoma have an impaired health-related quality of life (HRQOL). Exercise combined with nutritional support may improve this outcome. Careful evaluation of this supportive care strategy is needed to avoid burdening patients at this vulnerable stage with interventions that may offer no (meaningful) benefit. Therefore, this study aims to investigate the effects of a combined exercise and nutritional intervention on HRQOL in patients with incurable gastroesophageal adenocarcinoma. Methods: RADICES (the effect of exeRcise And Diet on quality of life in patients with Incurable Cancer of Esophagus and Stomach) is a multicenter randomized controlled trial aiming to include 196 patients with incurable gastroesophageal adenocarcinoma. Participants are randomly assigned (1:1) to a patient-tailored intervention or a control group. The intervention group is provided with 2 training sessions per week and biweekly nutritional consultations, delivered by trained physiotherapists and dietitians, during 12 weeks. The control group receives usual care supplemented with general physical activity advice. The primary outcome is the difference in HRQOL between the intervention group and the control group at 12 weeks, accounting for baseline HRQOL, measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–30 summary score. HRQOL is assessed at baseline, 6 weeks, 12 weeks, and every 3 months thereafter up to 1 year. Key secondary outcomes include patient-reported outcomes, cardiorespiratory fitness, dietary intake, disease progression, overall survival, and cost-effectiveness. Adherence and safety are monitored throughout the intervention period. Conclusion: This study will generate evidence on the effectiveness of a patient-tailored combined exercise and nutritional intervention in patients with incurable gastroesophageal adenocarcinoma. If effective for HRQOL, this intervention could be integrated into standard care for patients with incurable gastroesophageal adenocarcinoma. Trial registration: clinicaltrials.gov NCT06138223. Date of trial registration: November 18, 2023 Date and version study protocol: 28-04-2025 version 3.1 Date start recruitment: 19-01-2024
- Open Access
- 27 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
[18F]F-FAPI PET/CT and LAparoscopy in STagIng advanced gastric Cancer: a multicenter prospective study (PLASTIC-3 study)
Treatment decisions for locally advanced gastric adenocarcinoma rely on staging with gastroscopy, computed tomography (CT), and staging laparoscopy (SL). H
- 27 November 2025
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Open Access[18F]F-FAPI PET/CT and LAparoscopy in STagIng advanced gastric Cancer: a multicenter prospective study (PLASTIC-3 study)
Treatment decisions for locally advanced gastric adenocarcinoma rely on staging with gastroscopy, computed tomography (CT), and staging laparoscopy (SL). H
- Open Access
- 23 September 2025
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 282 (5) , 837-844
A Novel TRG-N Prognostic Classification System for Esophageal Cancer Undergoing Neoadjuvant Therapy Followed by Esophagectomy
Objective: To develop a new prognostic classification system centered on tumor regression grade (TRG) and ypN stage that can effectively stratify overall survival (OS) of esophageal cancer patients undergoing neoadjuvant therapy (NAT) followed by R0 esophagectomy. Summary Background Data: Although the prognostic value of combining TRG and ypN stage has been demonstrated, a prognostic classification system integrating these factors, trained using large-scale data, remains unavailable. Methods: Data from the Netherlands Cancer Registry (2015–2022) were analyzed. A new TRG-N prognostic classification system for OS was developed by grouping patients based on cN stage, ypN stage, and TRG. The prognostic performance of the TRG-N classification was compared with the 8th edition AJCC ypTNM classification using 4 comparative metrics (Log-rank χ², Linear trend χ², Akaike’s Information Criterion [AIC], and C-index). Results: A total of 3,193 patients were included. Among patients with adenocarcinoma, the TRG-N classification showed superior Linear trend χ² and AIC to the ypTNM classification. However, the Log-rank χ² of the TRG-N classification was inferior to that of the ypTNM classification, with no significant difference in the C-index (P-value=0.206) between the two systems. Among patients with squamous cell carcinoma, the TRG-N classification significantly outperformed the ypTNM classification in Log-rank χ², Linear trend χ², AIC, and C-index (P-value=0.018). Conclusion: The TRG-N classification demonstrated comparable prognostic performance to the AJCC ypTNM classification for esophageal adenocarcinoma but showed superior prognostic value for esophageal squamous cell carcinoma, making it a potentially more effective tool for risk stratification in esophageal cancer patients.
- 23 September 2025
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 282 (5) , 837-844
Open AccessA Novel TRG-N Prognostic Classification System for Esophageal Cancer Undergoing Neoadjuvant Therapy Followed by Esophagectomy
Objective: To develop a new prognostic classification system centered on tumor regression grade (TRG) and ypN stage that can effectively stratify overall survival (OS) of esophageal cancer patients undergoing neoadjuvant therapy (NAT) followed by R0 esophagectomy. Summary Background Data: Although the prognostic value of combining TRG and ypN stage has been demonstrated, a prognostic classification system integrating these factors, trained using large-scale data, remains unavailable. Methods: Data from the Netherlands Cancer Registry (2015–2022) were analyzed. A new TRG-N prognostic classification system for OS was developed by grouping patients based on cN stage, ypN stage, and TRG. The prognostic performance of the TRG-N classification was compared with the 8th edition AJCC ypTNM classification using 4 comparative metrics (Log-rank χ², Linear trend χ², Akaike’s Information Criterion [AIC], and C-index). Results: A total of 3,193 patients were included. Among patients with adenocarcinoma, the TRG-N classification showed superior Linear trend χ² and AIC to the ypTNM classification. However, the Log-rank χ² of the TRG-N classification was inferior to that of the ypTNM classification, with no significant difference in the C-index (P-value=0.206) between the two systems. Among patients with squamous cell carcinoma, the TRG-N classification significantly outperformed the ypTNM classification in Log-rank χ², Linear trend χ², AIC, and C-index (P-value=0.018). Conclusion: The TRG-N classification demonstrated comparable prognostic performance to the AJCC ypTNM classification for esophageal adenocarcinoma but showed superior prognostic value for esophageal squamous cell carcinoma, making it a potentially more effective tool for risk stratification in esophageal cancer patients.
- Open Access
- 7 June 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 225, 115568
Impact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors
- 7 June 2025
- Published by Elsevier in European Journal of Cancer
- Vol. 225, 115568
Open AccessImpact of immune-related adverse events on quality of life and physical functioning in older patients with solid tumors treated with immune checkpoint inhibitors
- Open Access
DOSAGE study: protocol for a phase III non-inferiority randomised trial investigating dose-reduced chemotherapy for advanced colorectal cancer in older patients
Introduction Treating older adults with chemotherapy remains a challenge, given their under-representation in clinical trials and the lack of robust treatment guidelines for this population. Moreover, older patients, especially those with frailty, have an increased risk of developing chemotherapy-related toxicity, resulting in a decreased quality of life (QoL), increased hospitalisations and high healthcare costs. Phase II trials have suggested that upfront dose reduction of chemotherapy can reduce toxicity rates while maintaining efficacy, leading to fewer treatment discontinuations and an improved QoL. The DOSAGE aims to show that upfront dose-reduced chemotherapy in older patients with metastatic colorectal cancer is non-inferior to full-dose treatment in terms of progression-free survival (PFS), with adaption of the treatment plan (monotherapy or doublet chemotherapy) based on expected risk of treatment toxicity. Methods and analysis The DOSAGE study is an investigator-initiated phase III, open-label, non-inferiority, randomised controlled trial in patients aged≥70 years with metastatic colorectal cancer eligible for palliative chemotherapy. Based on toxicity risk, assessed using the Geriatric 8 (G8) tool, patients will be stratified to either doublet chemotherapy (fluoropyrimidine with oxaliplatin) or fluoropyrimidine monotherapy. Patients classified as low risk will be randomised between a fluoropyrimidine plus oxaliplatin in either full-dose or with an upfront dose reduction of 25%. Patients classified as high risk will be randomised between fluoropyrimidine monotherapy in either full-dose or with an upfront dose reduction. In the dose-reduced arm, dose escalation after two cycles is allowed. The primary outcome is PFS. Secondary endpoints include grade≥3 toxicity, QoL, physical functioning, number of treatment cycles, dose reductions, hospital admissions, overall survival, cumulative received dosage and cost-effectiveness. Considering a median PFS of 8 months and non-inferiority margin of 8 weeks, we shall include 587 patients. The study will be enrolled in 36 Dutch Hospitals, with enrolment scheduled to start in July 2024. This study will provide new evidence regarding the effect of dose-reduced chemotherapy on survival and treatment outcomes, as well as the use of the G8 to choose between doublet chemotherapy or monotherapy. Results will contribute to a more individualised approach in older patients with metastatic colorectal cancer, potentially leading to improved QoL while maintaining survival benefits. Ethics and dissemination This trial has received ethical approval by the ethical committee Leiden Den Haag Delft (P24.018) and will be approved by the Institutional Ethical Committee of the participating institutions. The results will be disseminated in peer-reviewed scientific journals. Trial registration number NCT06275958.
Open AccessDOSAGE study: protocol for a phase III non-inferiority randomised trial investigating dose-reduced chemotherapy for advanced colorectal cancer in older patients
Introduction Treating older adults with chemotherapy remains a challenge, given their under-representation in clinical trials and the lack of robust treatment guidelines for this population. Moreover, older patients, especially those with frailty, have an increased risk of developing chemotherapy-related toxicity, resulting in a decreased quality of life (QoL), increased hospitalisations and high healthcare costs. Phase II trials have suggested that upfront dose reduction of chemotherapy can reduce toxicity rates while maintaining efficacy, leading to fewer treatment discontinuations and an improved QoL. The DOSAGE aims to show that upfront dose-reduced chemotherapy in older patients with metastatic colorectal cancer is non-inferior to full-dose treatment in terms of progression-free survival (PFS), with adaption of the treatment plan (monotherapy or doublet chemotherapy) based on expected risk of treatment toxicity. Methods and analysis The DOSAGE study is an investigator-initiated phase III, open-label, non-inferiority, randomised controlled trial in patients aged≥70 years with metastatic colorectal cancer eligible for palliative chemotherapy. Based on toxicity risk, assessed using the Geriatric 8 (G8) tool, patients will be stratified to either doublet chemotherapy (fluoropyrimidine with oxaliplatin) or fluoropyrimidine monotherapy. Patients classified as low risk will be randomised between a fluoropyrimidine plus oxaliplatin in either full-dose or with an upfront dose reduction of 25%. Patients classified as high risk will be randomised between fluoropyrimidine monotherapy in either full-dose or with an upfront dose reduction. In the dose-reduced arm, dose escalation after two cycles is allowed. The primary outcome is PFS. Secondary endpoints include grade≥3 toxicity, QoL, physical functioning, number of treatment cycles, dose reductions, hospital admissions, overall survival, cumulative received dosage and cost-effectiveness. Considering a median PFS of 8 months and non-inferiority margin of 8 weeks, we shall include 587 patients. The study will be enrolled in 36 Dutch Hospitals, with enrolment scheduled to start in July 2024. This study will provide new evidence regarding the effect of dose-reduced chemotherapy on survival and treatment outcomes, as well as the use of the G8 to choose between doublet chemotherapy or monotherapy. Results will contribute to a more individualised approach in older patients with metastatic colorectal cancer, potentially leading to improved QoL while maintaining survival benefits. Ethics and dissemination This trial has received ethical approval by the ethical committee Leiden Den Haag Delft (P24.018) and will be approved by the Institutional Ethical Committee of the participating institutions. The results will be disseminated in peer-reviewed scientific journals. Trial registration number NCT06275958.
- Open Access
- 29 January 2024
- Published by S. Karger AG in Gerontology
- Vol. 70 (4) , 337-350
Association of Biological Age with Tumor Microenvironment in Patients with Esophageal Adenocarcinoma
Introduction: Esophageal cancer is the seventh most common cancer worldwide and typically tends to manifest at an older age. Marked heterogeneity in time-dependent functional decline in older adults results in varying grades of clinically manifest patient fitness or frailty. The biological age-related adaptations that accompany functional decline have been shown to modulate the non-malignant cells comprising the tumor microenvironment (TME). In the current work, we studied the association between biological age and TME characteristics in patients with esophageal adenocarcinoma. Methods: We comparatively assessed intratumoral histologic stroma quantity, tumor immune cell infiltrate, and blood leukocyte and thrombocyte count in 72 patients stratified over 3 strata of biological age (younger <70 years, fit older ≥70 years, and frail older adults ≥70 years), as defined by a geriatric assessment. Results: Frailty in older adults was predictive of decreased intratumoral stroma quantity (B = −14.66% stroma, p = 0.022) relative to tumors in chronological-age-matched fit older adults. Moreover, in comparison to younger adults, frail older adults (p = 0.032), but not fit older adults (p = 0.302), demonstrated a lower blood thrombocyte count at the time of diagnosis. Lastly, we found an increased proportion of tumors with a histologic desert TME histotype, comprising low stroma quantity and low immune cell infiltration, in frail older adults. Conclusion: Our results illustrate the stromal-reprogramming effects of biological age and provide a biological underpinning for the clinical relevance of assessing frailty in patients with esophageal adenocarcinoma, further justifying the need for standardized geriatric assessment in geriatric cancer patients.
- 29 January 2024
- Published by S. Karger AG in Gerontology
- Vol. 70 (4) , 337-350
Open AccessAssociation of Biological Age with Tumor Microenvironment in Patients with Esophageal Adenocarcinoma
Introduction: Esophageal cancer is the seventh most common cancer worldwide and typically tends to manifest at an older age. Marked heterogeneity in time-dependent functional decline in older adults results in varying grades of clinically manifest patient fitness or frailty. The biological age-related adaptations that accompany functional decline have been shown to modulate the non-malignant cells comprising the tumor microenvironment (TME). In the current work, we studied the association between biological age and TME characteristics in patients with esophageal adenocarcinoma. Methods: We comparatively assessed intratumoral histologic stroma quantity, tumor immune cell infiltrate, and blood leukocyte and thrombocyte count in 72 patients stratified over 3 strata of biological age (younger <70 years, fit older ≥70 years, and frail older adults ≥70 years), as defined by a geriatric assessment. Results: Frailty in older adults was predictive of decreased intratumoral stroma quantity (B = −14.66% stroma, p = 0.022) relative to tumors in chronological-age-matched fit older adults. Moreover, in comparison to younger adults, frail older adults (p = 0.032), but not fit older adults (p = 0.302), demonstrated a lower blood thrombocyte count at the time of diagnosis. Lastly, we found an increased proportion of tumors with a histologic desert TME histotype, comprising low stroma quantity and low immune cell infiltration, in frail older adults. Conclusion: Our results illustrate the stromal-reprogramming effects of biological age and provide a biological underpinning for the clinical relevance of assessing frailty in patients with esophageal adenocarcinoma, further justifying the need for standardized geriatric assessment in geriatric cancer patients.